What Eli Lilly investors can learn from the slow launch of a competitor’s drug
The rollout of Alzheimer's treatment Leqembi from Biogen is going slower than expected, providing a read-through for Club stock Eli Lilly.
Source link
- Greece And Turkey’s Strategic Russian Air Defense Missiles Briefly In Spotlight
- The North Korean defectors finding fame in South Korea
